A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary care

Postgraduate Medical Journal

Volumn 83, Issue 983, 2007, Pages 602-605

  Dunkley, Alison ^a   Stone, Margaret ^a   Sayers, Robert ^b   Farooqi, Azhar ^a   Khunti, Kamlesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; EXERCISE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PRIMARY MEDICAL CARE; SMOKING; SMOKING CESSATION; VASCULAR SURGERY;

AGED; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HEALTH PROMOTION; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 34548742374     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.060806     Document Type: Article

References (15)

1. Department of Health. National Service Framework: coronary heart disease. London: Department of Health, 2000.
2. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 2000;320:1262-5.
3. Khunti K, Sorrie R, Jennings S, et al. Improving aspirin prophylaxis in post myocardial infarction patients in primary care: collaboration between a primary care audit group and a health authority in a multi-practice audit. BMJ 1999;319:297.
4. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998;316:1430-4.
5. Dunkley A, Stone M, Squire I, et al. An audit of secondary prevention of coronary heart disease in post acute myocardial infarction patients in primary care. Quality in Primary Care 2006;14:15-20.
6. De Lusignan S, Hague N, Belsey J, et al. The 'rule of halves' still applies to the management of cholesterol in cardiovascular disease. Br J Cardiol 2006;13:145-52.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
8. Huyen T, Anand S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004;292:1867-74.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
10. Mehler P, Coll J, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-6.
11. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
12. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Systematic Reviews 2005;(1):CD000990.
13. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Circulation 2002;106:1909-12.
14. Anon. Quality and Outcomes Framework CHD indicator data. 2005-6. http://www.ic.nhs.uk/services/qof.
15. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease. Edinburgh: SIGN; 2006, (SIGN publication no.89). http://www.sign.ac.uk (accessed 20 November 2006).